Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Suppression of allograft rejection by regulatory B cells induced via TLR signaling
Kang Mi Lee, Qiang Fu, Guoli Huai, Kevin Deng, Ji Lei, Lisa Kojima, Divyansh Agarwal, Peter van Galen, Shoko Kimura, Naoki Tanimine, Laura Washburn, Heidi Yeh, Ali Naji, Charles G. Rickert, Christian LeGuern, James F. Markmann
Kang Mi Lee, Qiang Fu, Guoli Huai, Kevin Deng, Ji Lei, Lisa Kojima, Divyansh Agarwal, Peter van Galen, Shoko Kimura, Naoki Tanimine, Laura Washburn, Heidi Yeh, Ali Naji, Charles G. Rickert, Christian LeGuern, James F. Markmann
View: Text | PDF
Research Article Immunology Transplantation

Suppression of allograft rejection by regulatory B cells induced via TLR signaling

  • Text
  • PDF
Abstract

B lymphocytes have long been recognized for their critical contributions to adaptive immunity, providing defense against pathogens through cognate antigen presentation to T cells and Ab production. More recently appreciated is that B cells are also integral in securing self-tolerance; this has led to interest in their therapeutic application to downregulate unwanted immune responses, such as transplant rejection. In this study, we found that PMA- and ionomycin-activated mouse B cells acquire regulatory properties following stimulation through TLR4/TLR9 receptors (Bregs-TLR). Bregs-TLR efficiently inhibited T cell proliferation in vitro and prevented allograft rejection. Unlike most reported Breg activities, the inhibition of alloimmune responses by Bregs-TLR relied on the expression of TGF-β and not IL-10. In vivo, Bregs-TLR interrupted donor-specific T cell expansion and induced Tregs in a TGF-β–dependent manner. RNA-Seq analyses corroborated the involvement of TGF-β pathways in Breg-TLR function, identified potential gene pathways implicated in preventing graft rejection, and suggested targets to foster Breg regulation.

Authors

Kang Mi Lee, Qiang Fu, Guoli Huai, Kevin Deng, Ji Lei, Lisa Kojima, Divyansh Agarwal, Peter van Galen, Shoko Kimura, Naoki Tanimine, Laura Washburn, Heidi Yeh, Ali Naji, Charles G. Rickert, Christian LeGuern, James F. Markmann

×

Figure 1

Phenotypic characterization of TLR-activated B cells.

Options: View larger image (or click on image) Download as PowerPoint
Phenotypic characterization of TLR-activated B cells.
(A) Purified splen...
(A) Purified splenic naive B cells were stimulated with the TLR9 agonist CpG (ODN 1668) for 3 days (Bregs-CpG) and with LPS, PMA, and ionomycin added for the last 5 hours (Bregs-TLR). Cell subsets are naive B cells (red), LPS-B cells (blue), Bregs-CpG (orange), Bregs-TLR (green), and control fluorescence minus one (FMO) (gray). Cell subsets were analyzed for expression of IgM, IgD, CD21, CD23, CD38, CD80, CD86, and MHC class II (I-Ab). Data are representative of independent experiments performed at least 3 times. (B) Flow cytometry analysis of regulatory B cell–associated markers. Frequency (% of positive cells/CD19+ B cells) of TIM1+, LAP+, CD25+, PD-L1+, and IL-10+ B cells (≥ 5 independent experiments). Data are expressed as mean. P values (1-way ANOVA): *P < 0.05, ***P < 0.001, and ****P < 0.0001. TIM1, T cell immunoglobin domain and mucin domain protein 1; LAP, latency-associated peptide.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts